Boosting the Endocannabinoid Anandamide Completely Reversed Social Impairment in Two Autism Mouse Models

Two mouse models of ASD were tested: BTBR mice and fmr1-/- mice (Fragile X model). Social behavior was assessed using the three-chambered social approach test, a standard paradigm measuring preference for social interaction. URB597 (FAAH inhibitor) was administered to increase anandamide levels. The CB1 receptor antagonist rimonabant was used to confirm receptor specificity. The elevated plus maze tested anxiety independently.

Autism spectrum disorder currently has no pharmacological treatment for its core symptom: social impairment. The finding that endocannabinoid enhancement reversed social deficits in two different genetic models suggests a potentially broad therapeutic approach that addresses the core of ASD rather than peripheral symptoms.

The connection between oxytocin, anandamide, and social reward represents a mechanistic framework that could transform ASD treatment. If the endocannabinoid system mediates social bonding through oxytocin, then pharmacologically enhancing this system could address the neurobiological root of social impairment rather than managing symptoms.

Mouse models of autism, while useful, cannot fully capture the complexity of human ASD. The three-chambered test measures social approach, which is only one aspect of social behavior. FAAH inhibitors have not been tested for social behavior in humans with ASD. The study used acute drug administration, not chronic treatment.